anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The control group are advised to manage the URTI as they normally do. A video on how to collect nasal swabs is shown. A nasal swab is collected. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document "not unwell" for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding.
The present invention relates to amide and urea derivatives of heteroaryl- substituted diazatricycloalkanes, of the Formula (I) with the definition as set out in the description pharmaceutical compositions including the compounds, methods of preparing the compounds, and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the ??7 nAChR subtype by administering one or more of the compounds to treat or prevent disorders mediated by the ??7 nAChR subtype. The diazatricycloalkanes typically consist of a 1-azabicyclooctane fused to pyrrolidine ring. The substituent heteroaryl groups are 5- or 6-membered ring heteroaromatics, such as 3-pyridinyl and 5-pyrimidinyl moieties, which are attached directly to the diazatricycloalkane. The secondary nitrogen of the pyrrolidine moiety is substituted with an arylcarbonyl (amide type derivative) or an arylaminocarbonyl (N- arylcarbamoyl) (urea type derivative) group. The compounds are beneficial in therapeutic applications requiring a selective interaction at certain nAChR subtypes. That is, the compounds modulate the activity of certain nAChR subtypes, particularly the ??7 nAChR subtype, and do not have appreciable activity toward muscarinic receptors. Radiolabeled versions of the compounds can be used in diagnostic methods.
FIELD: medicine; pediatrics. SUBSTANCE: method involves general invigorating therapy combined with treatment with the use of special balsam. The balsam is water- or oil-base emulsion administered into the straight intestine (at least one daily dose of 5-10 ml after using a clyster. The emulsion concentration is gradually increased from 10% to 50%. This treatment generally results in normal defecation within 5-10 days. EFFECT: faster restoration of activity of intestinal epithelium cells.
The aim of this study was to investigate the effectiveness of decisional quality and decisional control preferences by using a specific question prompt list (QPL) during a shared decision-making consultation among facing decision for dialysis in end-stage renal disease (ESRD) patients. A randomized controlled trial was conducted at the university medical center of North Taiwan. Recruit subjects are those who are about to receive the nurse-led coaching of shared decision-making (SDM) for patients with ESRD and attend the program. By using blocked Randomization design, the investigators assigned participants to QPL group or usual care. Prior to a clinic visit to discuss treatment, two-pages ESRD QPL leaflets are provided to QPL group, while usual care group without receiving provision of QPL. Measurements of outcome included decision quality (decision conflict, decisional self-efficiency) and decision control preference at before the counseling (T0), immediately after counseling (T1), and evaluate decision regret at one month after treatment (T2), at this time the patient has decided and started to accept the selected treatment (hemodialysis, peritoneal dialysis or conservative treatment). All statistical analyses were performed in SAS statistical software, version 9.4 (SAS, Cary, NC). The effects of the intervention were assessed by generalized estimating equation (GEE) analysis with the coefficient of interaction ( group × time) term. Statistical tests were two-sided with a significance level of 0.05. Hierarchical Linear Model was used to detect the impact of nested within physician.
The investigators will determine the effects of exercising at two different intensities (compared to a control non-exercise condition) on neuroplastic potential in depressed and non-depressed subjects. To accomplish this aim, the investigators will have subjects ride a cycle ergometer at intensities set to elicit 35% (low) and 70% (high) of heart rate reserve (((220 - age) - resting heart rate) x 35% or 70%) + resting heart rate). Prior to, and immediately after exercise participants will have their neuroplastic potential tested via transcranial magnetic stimulation (TMS), blood specimens sampled, and mood changes assessed (methods detailed below). These assessments will occur at these time points and then every 15 minutes for 1 hour after exercise.

Neuroplastic potential will be assessed using TMS. TMS-induced motor evoked potentials (MEP's) will be recorded from the abductor pollicis brevis as a way to measure changes in the excitability of the corticospinal tract in response to exercise and paired associative stimulation. Serum brain-derived neurotrophic factor (BDNF) and cortisol levels will be obtained through blood specimen samples in order to examine the potential exercise-induced changes in known stress- and neuroplasticity-related biomarkers. Mood and affect will be surveyed using the Activation-Deactivation Checklist (AD ACL), feeling scale (FS), and felt arousal scale (FAS). These measures will permit the assessment of exercise-induced changes in mood and affect.
Chlordiazepoxide hydrochloride is the prototype for the benzodiazepine compounds. It is a versatile therapeutic agent of proven value for the relief of anxiety. Chlordiazepoxide hydrochloride is among the safer of the effective psychopharmacologic compounds available, as demonstrated by extensive clinical evidence.

Chlordiazepoxide hydrochloride is 7-chloro-2- (methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide hydrochloride. A white to practically white crystalline substance, it is soluble in water. It is unstable in solution and the powder must be protected from light. The structural formula is:

C16H14ClN3O • HCl M.W. 336.22

Each capsule, for oral administration, contains either 5 mg, 10 mg or 25 mg of chlordiazepoxide hydrochloride, USP and has the following inactive ingredients: anhydrous lactose, D&C yellow no. 10, FD&C blue no. 1, FD&C blue no. 1 aluminum lake, gelatin, hydrogenated vegetable oil, microcrystalline cellulose, pharmaceutical glaze, and titanium dioxide. The 5 mg and 25 mg also contain D&C yellow no. 10 aluminum lake, FD&C blue no. 2 aluminum lake, FD&C red no. 40 aluminum lake, propylene glycol, and synthetic black iron oxide. In addition, the 5 mg contains D&C red no. 33 and the 10 mg also contains butyl paraben, edetate calcium disodium, dimethyl polysiloxane, ethylene glycol monoethyl ether, FD&C red no. 40, methyl paraben, propyl paraben, sodium, sodium lauryl sulfate, sodium propionate, and soya lecithin.
A method of making a composite pigment of precipitated calcium carbonate (PCC) and a silicon compound, in which the resulting composite pigment is endowed with an excellent combination of optical and mechanical properties. Among other things, a PCC/silicate composite pigment made according to this invention imparts increased bulk, light scattering power, porosity and printing properties to paper. The composite pigment material made according to this invention also is very competitive from the standpoint of its production cost. The method for making the composite pigment includes the step of introducing a soluble silicate compound into an aqueous medium containing a precipitate of calcium carbonate formed by carbonation of lime milk, and at a time when the calcium carbonate precipitation reaction has progressed to near completion. Then, an insoluble silicon compound is precipitated upon the precipitated calcium carbonate by carbonation of the reaction mixture in a manner in which the maximum temperature variation of the reaction mixture is kept less than 20° C. The soluble silicate compound is added when the precipitation of the calcium carbonate has reached approximately 90% to less than 100% of completion. Further, the temperature of the reaction mixture during deposition of the silicon compound upon the precipitated calcium carbonate is at least 50° C. or greater, and more preferably is kept between approximately 60 to 100° C.
PURPOSE: To obtain an antitumor agent by using a 3-keto compound of triterpenes as an active ingredient. CONSTITUTION: This antitumor agent comprises containing a 3-keto compound of oleanane-type triterpenes expressed by formula I (R is H, an alkyl or a saccharide), 3-keto oleanolic acid or an ester thereof as an active ingredient and a 3-keto compound of damarane type triterpenes expressed by formula II, 3-keto-20(S)-protopanaxadiol as an active ingredient. The agent can suppress the growth of melanoma cells, uterine cervical carcinoma cells, lung cancer cells, ascitic tumor cells, Morris hepatoma cells, etc., in mice. The oleanane-type triterpenes are obtained by extracting plants containing saponin (e.g. a ginseng for medicinal use) and conducting chemical and enzymatic treatments of the extract.  The 3-keto compound of dammarane type triterpenes is obtained by extracting the green leaves of white birch, etc., as raw materials, then conducting chemical and/or enzymatic treatments and then conducting an oxidative treatment of the extract.
The present invention relates to a bedsore ointment for curing bedsores and a preparation method thereof. The bedsore ointment comprises Chinese angelica, frankincense, myrrh, dahurian angelica roots, red halloysite, bletilla tubers, dragon blood, borneol, calomelas, alkanna tinctoria, vaseline and benne oil. The bedsore ointment has the preparation method comprising the following steps: 1) the Chinese angelica, the frankincense, the myrrh, the dahurian angelica roots, the red halloysite, the bletilla tubers and the alkanna tinctoria are put in a container, and the benne oil is added to the container; the mixture is soaked; 2) the mixture is boiled for a plurality of minutes by intense fire; 3) after the mixture is placed and cooled, the vaseline is added to the mixture to be boiled for a plurality of minutes; 4) the mixture is cooled after deslagging; 5) the dragon blood, the borneol and the calomelas are added to the mixture to be stirred and boiled for a plurality of minutes by slight fire; 6) the mixture is disinfected by high pressure after being cooled. The present invention uses traditional Chinese medicine as the main components, and the traditional Chinese medicine has the functions of blood circulation activation, blood stasis dissipation, detoxication, analgesia, skin moisture and muscle regeneration. Therefore, the bedsore ointment has the advantages of high safety and reliability, conspicuous curative effect, low price and no poison. The bedsore ointment has notable curative effects on the bedsores and all disease symptoms of superficial infection ulcers which can not be easily healed by clinical application and cure. In addition, the preparation method of the bedsore ointment is simple and convenient and has low cost.
Abnormal lung development can cause congenital pulmonary cysts, the mechanisms of which remain largely unknown. Although the cystic lesions are believed to result directly from disrupted airway epithelial cell growth, the extent to which developmental defects in lung mesenchymal cells contribute to abnormal airway epithelial cell growth and subsequent cystic lesions has not been thoroughly examined. In the present study using genetic mouse models, we dissected the roles of bone morphogenetic protein (BMP) receptor 1a (Bmpr1a)-mediated BMP signaling in lung mesenchyme during prenatal lung development and discovered that abrogation of mesenchymal Bmpr1a disrupted normal lung branching morphogenesis, leading to the formation of prenatal pulmonary cystic lesions. Severe deficiency of airway smooth muscle cells and subepithelial elastin fibers were found in the cystic airways of the mesenchymal Bmpr1a knockout lungs. In addition, ectopic mesenchymal expression of BMP ligands and airway epithelial perturbation of the Sox2-Sox9 proximal-distal axis were detected in the mesenchymal Bmpr1a knockout lungs. However, deletion of Smad1/5, two major BMP signaling downstream effectors, from the lung mesenchyme did not phenocopy the cystic abnormalities observed in the mesenchymal Bmpr1a knockout lungs, suggesting that a Smad-independent mechanism contributes to prenatal pulmonary cystic lesions. These findings reveal for the first time the role of mesenchymal BMP signaling in lung development and a potential pathogenic mechanism underlying congenital pulmonary cysts.
An envelope contains active products (lipophiles or hydrophiles) absorbed on non-woven fabric for underclothing which absorbs the prods. and transmits them to the skin. The envelope is sealed and consists of an outer skin with an internal fabric lining contng. the prods. The underclothing of absorbant fibres is placed in the envelope and contacted with the fabric before wearing. The underclothing protects the skin by regulated osmotic diffusion of the active prods.
This is a study to collect information on adverse events (side effects) that occur during treatment with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (CRPC). To participate in this study patients must have failed 1 or 2 chemotherapy regimens (1 of which contained a taxane such as docetaxel), reside in an area where abiraterone acetate is not yet available through local healthcare providers, and not be eligible for enrollment in any other ongoing clinical research study of abiraterone acetate. CRPC is progressive form of prostate cancer where the cancer cells become resistant to hormonal therapies that are designed to block the release or uptake of testosterone and the cancer cells metastasize (ie, spread to other parts of the body). Abiraterone acetate (referred to as abiraterone) is a drug currently under development for use in treating men with CRPC. Patients will be treated with abiraterone and prednisone daily until progression of clinical disease (ie, includes signs of clinical disease progression and/or clinical disease progression confirmed by radiographic and prostate-specific antigen \[PSA\] test results). Other reasons for discontinuation of treatment may include adverse events reported, initiation of other anticancer therapies, or the patient's inability to comply with dosing instructions. Patients will be followed for 30 days after the discontinuation of treatment with abiraterone acetate. Patients will take four 250-mg tablets of abiraterone orally at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day. Patients will also take 5 mg of oral prednisone, twice daily. Each treatment cycle consists of 28 days and patients will take abiraterone continually on a daily basis until disease progression is observed at which time abiraterone will be discontinued and the dose of prednisone reduced if clinically indicated.
The were 743 subjects were sampled from Maywood, Il. There was no intervention.
Epidermodysplasia verruciformis (EV) is a rare genetic skin disorder that is characterized by the development of papillomavirus-induced skin lesions that can progress to squamous cell carcinoma (SCC). Certain high-risk, cutaneous β-genus human papillomaviruses (β-HPVs), in particular HPV5 and HPV8, are associated with inducing EV in individuals who have a homozygous mutation in one of three genes tied to this disease: EVER1, EVER2, or CIB1. EVER1 and EVER2 are also known as TMC6 and TMC8, respectively. Little is known about the biochemical activities of EVER gene products or their roles in facilitating EV in conjunction with β-HPV infection. To investigate the potential effect of EVER genes on papillomavirus infection, we pursued in vivo infection studies by infecting Ever2-null mice with mouse papillomavirus (MmuPV1). MmuPV1 shares characteristics with β-HPVs including similar genome organization, shared molecular activities of their early, E6 and E7, oncoproteins, the lack of a viral E5 gene, and the capacity to cause skin lesions that can progress to SCC. MmuPV1 infections were conducted both in the presence and absence of UVB irradiation, which is known to increase the risk of MmuPV1-induced pathogenesis. Infection with MmuPV1 induced skin lesions in both wild-type and Ever2-null mice with and without UVB. Many lesions in both genotypes progressed to malignancy, and the disease severity did not differ between Ever2-null and wild-type mice. However, somewhat surprisingly, lesion growth and viral transcription was decreased, and lesion regression was increased in Ever2-null mice compared with wild-type mice. These studies demonstrate that Ever2-null mice infected with MmuPV1 do not exhibit the same phenotype as human EV patients infected with β-HPVs.IMPORTANCEHumans with homozygous mutations in the EVER2 gene develop epidermodysplasia verruciformis (EV), a disease characterized by predisposition to persistent β-genus human papillomavirus (β-HPV) skin infections, which can progress to skin cancer. To investigate how EVER2 confers protection from papillomaviruses, we infected the skin of homozygous Ever2-null mice with mouse papillomavirus MmuPV1. Like in humans with EV, infected Ever2-null mice developed skin lesions that could progress to cancer. Unlike in humans with EV, lesions in these Ever2-null mice grew more slowly and regressed more frequently than in wild-type mice. MmuPV1 transcription was higher in wild-type mice than in Ever2-null mice, indicating that mouse EVER2 does not confer protection from papillomaviruses. These findings suggest that there are functional differences between MmuPV1 and β-HPVs and/or between mouse and human EVER2.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition capable of reinforcing a keratinous material such as a nail, eyelashes or hair. SOLUTION: This cosmetic composition is obtained by formulating a colloidal silicic acid in an amount of 0.1-5 wt.%, preferably 1-2 wt.% based on the total weight of the composition in a cosmetic medium. The colloidal silicic acid is selected from hydrophilic igneous silica, hydrophobic igneous silica or silica treated on the surface by an organic treatment. A film-forming substance (e.g. nitrocellulose) and a solvent (e.g. ethyl acetate), a plasticizer (e.g. a citrate), an oily medium (e.g. a silicone oil), an activator, a colorant, etc., are further suitably formulated therewith. The colloidal silicic acid can be prepared as the form applied to a nail such as an enamel for the nail, base or the base for care, the form applied to eyelashes such as a mascara or a product for hair such as a styling mousse, a lotion or a hair spray.  The nail can be made harder and stronger by using the composition without cracking or crazing.
FIELD: perfume-cosmetic industry. SUBSTANCE: emulsion "oil-in-water" for cosmetic and dermatological agents has gel-forming agent and thermoplastic hollow swollen particles of polymer or acrylonitrile copolymer providing dispersion of an oily phase in an aqueous gel-like phase. These particles are mainly particles of the swollen copolymer of acrylonitrile and acrylic or styrene monomer and/or vinylidene chloride. Emulsion provides skin and hair care and cleansing and skin making up also. EFFECT: improved quality of emulsion. 20 cl, 1 tbl, 7 ex
PURPOSE: A composition containing HVEM inhibitors is provided to be used as a therapeutic agent for treating bone diseases. CONSTITUTION: A composition for promoting bone differentiation or osteogenesis contains HVEM(herpesvirus-entry mediator) gene expression inhibitor or HVEM protein activation inhibitor. The HVEM gene contains a base sequence of sequence number 1. The HVEM inhibitor is an antisense oligonucleotide, siRNA, or shRNA. A composition for preventing or treating bone diseases contains the composition as an active ingredient. A method for predicting or diagnosing risk of developing bone diseases comprises: a step of measuring HVEM gene expression level or HVEM protein level in a biological sample; and a step of comparing gene expression level or protein level between the biological sample and a control group.
Tics in patients with ADHD and comorbid Tourette's Disorder 

Atomoxetine administered in a flexible dose range of 0.5 to 1.5 mg/kg/day (mean dose of 1.3 mg/kg/day) and placebo were compared in 148 randomized pediatric (age 7-17 years) subjects with a DSM-IV diagnosis of ADHD and comorbid tic disorder in an 18 week, double-blind, placebo-controlled study in which the majority (80%) enrolled in this trial with Tourette's Disorder (Tourette's Disorder: 116 subjects; chronic motor tic disorder: 29 subjects). A non-inferiority analysis revealed that atomoxetine did not worsen tics in these patients as determined by the Yale Global Tic Severity Scale Total Score (YGTSS). Out of 148 patients who entered the acute treatment phase, 103 (69.6%) patients discontinued the study. The primary reason for discontinuation in both the atomoxetine (38 of 76 patients, 50.0%) and placebo (45 of 72 patients, 62.5%) treatment groups was identified as lack of efficacy with most of the patients discontinuing at Week 12. This was the first visit where patients with a CGI-S≥4 could also meet the criteria for "clinical non-responder" (CGI-S remained the same or increased from study baseline) and be eligible to enter an open-label extension study with atomoxetine. There have been postmarketing reports of tics [see ADVERSE REACTIONS (6.2)].
Anastomotic leakage after pancreaticoduodenectomy is a feared complication with substantial mortality and morbidity. Treatment of a postoperative pancreatic fistula can be difficult and management may range from a simple observation with or without percutaneous drainage, to the urgent need for reoperation and management of abdominal sepsis with organ failure and prolonged intensive care. To diagnose a pancreatic fistula may have a delay of several days. The risk of death and severe morbidity raises considerable from a biochemical pancreatic fistula compared to the most serious form, a grade C. Also, the cost of managing a patient with a fistula is 1.3-6 times more than a patient with no complications after PD.

Microdialysis is a promising tool in patients who undergoes pancreaticoduodenectomy for early detection of postoperative pancreatic fistula development. The technique may reveal an fistula before severe symptoms occur and before the complication gives the patient serious and life-threatening symptoms. Earlier intervention of the postoperative pancreatic fistula may lead to better prognosis, less reoperations and interventions and shorter stay at the ICU/hospital. By monitoring intraperitoneal metabolites (glycerol, lactate, pyruvate and glucose) close to the pancreaticojejunostomy, signs of a leakage may be discovered in few hours, thereby make it possible for early intervention and prevent developement of serious progression of morbidity. The investigators want to perform a randomized study where half of the patients will receive a microdialysis catheter implanted close to the pancreaticoduodenal anastomosis before closure of the abdomen. At certain timepoints postoperatively microdialysate will be analyzed for glycerol, lactate, pyruvate and glucose and the data will be used in the decisionmaking of diagnosing a pancreatic anastomosis leakage in addition to standard management. The other half of the patients will not receive a microdialysis catheter and the decisionmaking will only be based on standard management (ie. inflammation markers in blood samples, amylase in drainage fluid).
Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received sugar pills.